GUARDANT HEALTH has partnered with SWOG on a study to use cell-free DNA testing to identify mechanisms of resistance and future treatment options in non-small cell lung cancer. SWOG chose Guardant360 as the blood test for a tumor genomic profiling study of approximately 600 lung cancer patients. The study will test patients at the time...
A curious piece of paper hangs in a frame outside the director’s office at University of Iowa Holden Comprehensive Cancer Center on the second floor of the General Hospital.
